LZ-SAA 'Eiken'

Dear valued customers who are currently using LZ-SAA ‘Eiken’ Japanese package,

We would like to inform you that the specifications of LZ-SAA ‘Eiken’ are planned to change as follows:

  • -        The assigned value is set traceable to WHO International Standard SERUM AMYLOID A (SAA) 1st International Standard NIBSC code: 92/680. The measured value will be approx. 44% of the conventional product with human serum.
  • -        The assigned value to Calibrator is variable per lot.
  • -        The unit is changed from “μg/mL” to “mg/L” to comply the WHO International Standard.
  • -        The language on package is changed from Japanese to English.
  • -        All products is intended use for research use only.

However, please note that there is no change in components for all products.

Please find the following information from here.

  • -        Calibration hierarchy (traceability)
  • -        Correlation between LZ-SAA Japanese package (conventional method) and RUO LZ TEST EIKEN SAA (English package).

LZ-SAA ‘Eiken’ is intended use for measurement of SAA in serum and plasma of human. For application in veterinary, please use VET-SAA ‘Eiken’ optimized for measurement of multispecies SAA. VET-SAA is the assay developed by confirming cross-reactivity to horse, cat, dog, and cow.

To customers who want to purchase LZ-SAA directly from us:  It may take several months from ordering to delivery. Please contact us for the details.


Serum amyloid A (SAA) assay

Research Use Only

LZ-SAA 'Eiken'

LZ-SAA is a latex turbidimetric immunoassay reagent to measure serum amyloid A (SAA) in serum and plasma of human on general chemistry analyzers. This product is for research use only and not for in vitro diagnostics use except Japanese IVD regulation.

Serum amyloid A (SAA) – inflammation biomarker

  • - Acute phase protein synthesized in the liver when inflammation occurs
  • - Dramatical change up to 1000 folds reflecting inflammation

SAA impact on diseases under research

  • Viral infection and COVID-19
  • SAA might be highly sensitive with both viral and bacterial infection, despite C-reactive protein (CRP) remains low in viral infection [*1, 2]. Current studies show SAA level indicates severity of COVID-19.   >Read more
  • Inflammatory bowel diseases (IBD)
  • SAA might be the more sensitive serum biomarker in monitoring disease activity of ulcerative colitis and Crohn’s disease than CRP and other inflammatory markers [*3, 4].   > Read more
  • Pediatric diseases
  • Significant increase of SAA was reported in neonatal sepsis even at early-onset of inflammation, and the change occurs more rapidly than that of CRP and procalcitonin [*5, 6]. Likewise, SAA showed greater change when SAA and CRP were compared in children with acute viral infections [*7].
  • Rheumatoid arthritis (RA)
  • Studies indicate SAA levels reflect disease activity and assessment of treatment response of RA better than CRP and erythrocyte sedimentation rate (ESR) [*8, 9, 10].

Product information

LZ-SAA ‘Eiken’ is our unique LA-TIA reagent for general clinical chemistry analyzers. It has been used at common clinical laboratories in Japan for more than 20 years.

We would like to support research on SAA. Please feel free to contact us to know availability for purchase!

Code No. Product Name Units Storage IFU

R1: 2 x 20mL

R2: 2 x 20mL
2-10°C PDF >
V-SZ12 RUO LZ-SAA Calibrator EIKEN 1mLx6 2-8°C PDF >
V-SZ13 RUO QC-SAA L EIKEN 2mL x5 2-8°C PDF >
V-SZ14 RUO QC-SAA H EIKEN 2mL x5 2-8°C

*These products are research use only. Not for human in vitro diagnostic use.

For veterinary use


  1. Nakayama T, Sonoda S, Urano T, et al. Monitoring both serum amyloid protein A and C-reactive protein as inflammatory markers in infectious diseases. Clin Chem. 1993 Feb;39(2):293-7.
  2. Yip TT, Chan JW, Cho WC, et al. Protein chip array profiling analysis in patients with severe acute respiratory syndrome identified serum amyloid a protein as a biomarker potentially useful in monitoring the extent of pneumonia. Clin Chem. 2005 Jan;51(1):47-55.
  3. Chambers RE, Stross P, Barry RE, Whicher JT. Serum amyloid a protein compared with C-reactive protein, alpha 1-antichymotrypsin and alpha 1- acid glycoprotein as a monitor of inflammatory bowel disease. Eur J Clin Investig. 1987;17:460–7.
  4. Niederau C, Backmerhoff F, Schumacher B, Niederau C. Inflammatory mediators and acute phase proteins in patients with Crohn’s disease and ulcerative colitis. Hepatogastroenterology. 1997;44:90–107.
  5. Arnon, S., Litmanovitz, I., Regev, R. et al. Serum amyloid A: an early and accurate marker of neonatal early-onset sepsis. J Perinatol 27, 297–302 (2007).
  6. Çetinkaya, M., Özkan, H., Köksal, N. et al. Comparison of serum amyloid A concentrations with those of C-reactive protein and procalcitonin in diagnosis and follow-up of neonatal sepsis in premature infants. J Perinatol 29, 225–231 (2009).
  7. Miwata H, Yamada T, Okada M, et al. Serum amyloid A protein in acute viral infections. Arch Dis Child. 1993;68(2):210-214. 
  8. Chambers RE, MacFarlane DG, Whicher JT, Dieppe PA. Serum amyloid-A protein concentration in rheumatoid arthritis and its role in monitoring disease activity. Ann Rheum Dis. 1983 Dec;42(6):665-7.
  9. Cunnane G, Grehan S, Geoghegan S, et al. Serum amyloid A in the assessment of early inflammatory arthritis. J Rheumatol. 2000 Jan;27(1):58-63.
  10. Hwang YG, Balasubramani GK, Metes ID, et al. Differential response of serum amyloid A to different therapies in early rheumatoid arthritis and its potential value as a disease activity biomarker. Arthritis Res Ther. 2016 May 17;18(1):108.

Related pages

Contact us

  Select a Topic
  First Name
  Last Name
  Email Address